Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2000

View Archived Issues

Age and gender found to have significant effects on cardiovascular disease treatment outcomes

Chugai becomes eighth Japanese company to receive license for PDL patent

SkyePharma and Merck sign agreement for Geomatrix

Adderall reduces symptoms of ADHD more effectively than Ritalin

Angiotech signs license agreement with Alcon for delivery of paclitaxel

Boston Life Sciences achieves milestone in experimental spinal cord injury

Elan acquires Segix Italia

Angiogenesis inhibitor shows promise in Kaposi's sarcoma

AEterna begins recruiting for NIH-sponsored clinical trial with new lung cancer drug

Alexion reports on complement activation in cardiovascular disease and kidney damage

Onconase may be associated with survival benefit versus doxorubicin in certain UMM patients

Trial demonstrates efficacy of drug therapy and cognitive-behavioral therapy in panic disorder

Morphine dependency in mice blocked by the kappa-opioid receptor agonist TRK-820

CDP-571 results in Crohn's disease presented at DDW

Herbal preparation shows promise in IBS

Xoma highlights Q1 development progress

BXT-51072 shows potent antioxidant activity in active ulcerative colitis

EGF-genistein prevents restenosis in vivo

Infliximab acts as steroid-sparing agent in Crohn's disease

Novo Nordisk outlicenses Neurin class of compounds to ReNeuron

Genentech's rhuMAb-VEGF shows promise on several fronts; phase III trials in planning

Phase I results of Genta's lead antisense drug combined with chemotherapy reported at ASCO

Takeda describes new injectable antifungal agents

BE-54476, a new antibacterial substance produced by a species of Streptomyces

Microbially produced NO inhibitor presented by Pola

Duphar patent describes combination of activities useful for Rx of schizophrenia

Potent histamine H3 receptor ligands developed by Schering-Plough

Abbott synthesizes series with adenosine kinase-inhibitory activity

New compounds for inflammation emerge from R&D at the former Searle

Inhibitors of COX-2 with an imidazole structure revealed by Uriach